Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Contrave, also marketed as Mysimba is an extended release fixed dose combination of naltrexone HCL/bupropion HCL indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.
Product Name : Contrave
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2023
Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Hamden Group
Deal Size : Undisclosed
Deal Type : Agreement
Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals
Details : Under this agreement, Hamden will have worldwide exclusive rights to sell, market and distribute the HALB patented low-dose Naltrexone medication, and the HALB proprietary Vita-Shield-Max TM Nutraceutical Product.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 14, 2022
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Hamden Group
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 1 clinical trial data showed that SP-104 (naltrexone hydrochloride) treated healthy volunteers and had lower rates of adverse events, as compared with immediate release naltrexone -treated volunteers.
Product Name : SP-104
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2022
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Immune Therapeutics
Deal Size : $402.0 million
Deal Type : Agreement
Details : Statera will receive milestones, new indications and royalties, Crohn’s disease and COVID-19 indications and regulatory approvals, payments from Immune Therapeutics in exchange for Statera’s rights to any product containing low-dose naltrexone as an ...
Product Name : STAT-205
Product Type : Other Small Molecule
Upfront Cash : $2.0 million
April 27, 2022
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Immune Therapeutics
Deal Size : $402.0 million
Deal Type : Agreement
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STAT-205 may show promise in treating both acute COVID infections and long COVID in this manner. Preliminary in vitro data demonstrated the drug’s ability to slow or halt the progression of SARS-CoV-2 (the virus that causes COVID-19) in human lung cell...
Product Name : STAT-205
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2022
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baclofen,Naltrexone Hydrochloride
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYVISPAH is bioequivalent to oral baclofen tablets and provides flexible, a skeletal muscle relaxant, is well established for the treatment of spasticity and spinal cord injuries.
Product Name : Lyvispah
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : Baclofen,Naltrexone Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CX-101 is an investigational drug that is being studied for smoking cessation.The Phase 3 program builds on the successful Phase 2b findings and evaluates a mixed-weight population at a fixed-dose combination of CX-101 (naltrexone/bupropion 32 mg/360 mg ...
Product Name : Contrave
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2021
Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : During preclinical in vitro studies, STAT-205 demonstrated an ability to inhibit the replication of coronaviruses in human lung cells. Data also shows that STAT-205 could prevent life-threatening lung inflammation caused by COVID-19, as well as lessen th...
Product Name : STAT-205
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
